#### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Proposed Single Technology Appraisal**

# Sapropterin for treating phenylketonuria ID1475

# Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or
	appeal)
<ul> <li>Company</li> <li>BioMarin (sapropterin)</li> <li>Patient/carer groups</li> <li>Genetic Alliance UK</li> <li>Muslim Council of Britain</li> <li>PHED UP</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>The National Society for Phenylketonuria</li> <li>Professional groups</li> <li>Association of Genetic Nurses &amp; Counsellors</li> <li>British Dietetic Association</li> <li>British Geriatrics Society</li> <li>British Inherited Metabolic Disease Group</li> <li>British Psychoanalytic Council</li> <li>British Society for Genetic Medicine</li> </ul>	, ,

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

# PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Provisional matrix for the proposed technology appraisal of sapropterin for treating phenylketonuria ID1475. Issue date: August 2018

#### **Definitions:**

# **Consultees**

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

# Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary.

All non-company commentators are invited to nominate clinical specialists or patient experts.

Provisional matrix for the proposed technology appraisal of sapropterin for treating phenylketonuria ID1475. Issue date: August 2018

<sup>&</sup>lt;sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.